Wockhardt has developed comprehensive ‘concept-to-market’ strengths in all facets of recombinant biotechnology. These include gene-cloning, development of production strains, expertise in all three major expression systems, purification, downstream processing and testing.

Wockhardt’s prowess in biotechnology is evident in its success in developing six biopharmaceutical products.

Product Indication Erythropoietin Severe Anaemia in the case of cancer and chronic renal failure Recombinant Human Insulin Diabetes Hepatitis B Vaccine Hepatitis B Interferon alpha 2B Antiviral Granulocyte Colony Stimulating Factor (G-CSF) Growth Factor Glargine Long Acting Insulin Analog

Wockhardt Biopharmaceutical Pipeline

For a more in-depth look at Wockhardt’s Biotechnology plans and prowess, click here >>